BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 11498833)

  • 21. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):495S-501S. PubMed ID: 12538506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases.
    Cutuli B; De Lafontan B; Kirova Y; Auvray H; Tallet A; Avigdor S; Brunaud C; Delva C
    Radiat Oncol; 2015 May; 10():110. PubMed ID: 25944033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.
    Lazzeroni M; Puntoni M; Guerrieri-Gonzaga A; Serrano D; Boni L; Buttiron Webber T; Fava M; Briata IM; Giordano L; Digennaro M; Cortesi L; Falcini F; Serra P; Avino F; Millo F; Cagossi K; Gallerani E; De Simone A; Cariello A; Aprile G; Renne M; Bonanni B; DeCensi A
    J Clin Oncol; 2023 Jun; 41(17):3116-3121. PubMed ID: 36917758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tamoxifen in ductal carcinoma in situ.
    Daly MB
    Semin Oncol; 2006 Dec; 33(6):647-9. PubMed ID: 17145343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is sentinel node biopsy necessary in conservatively treated DCIS?
    Julian TB; Land SR; Fourchotte V; Haile SR; Fisher ER; Mamounas EP; Costantino JP; Wolmark N
    Ann Surg Oncol; 2007 Aug; 14(8):2202-8. PubMed ID: 17534687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy.
    Giannakeas V; Sopik V; Narod SA
    JAMA Netw Open; 2018 Aug; 1(4):e181100. PubMed ID: 30646103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives.
    Sakorafas GH; Tsiotou AG
    Cancer Treat Rev; 2000 Apr; 26(2):103-25. PubMed ID: 10772968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators.
    Fisher ER; Costantino J; Fisher B; Palekar AS; Redmond C; Mamounas E
    Cancer; 1995 Mar; 75(6):1310-9. PubMed ID: 7882281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06.
    Deutsch M; Land SR; Begovic M; Wieand HS; Wolmark N; Fisher B
    Cancer; 2003 Oct; 98(7):1362-8. PubMed ID: 14508821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials.
    Viani GA; Stefano EJ; Afonso SL; De Fendi LI; Soares FV; Leon PG; Guimarães FS
    Radiat Oncol; 2007 Aug; 2():28. PubMed ID: 17683529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of surgery, radiation, and systemic treatment on outcomes in patients with ductal carcinoma in situ.
    Kane RL; Virnig BA; Shamliyan T; Wang SY; Tuttle TM; Wilt TJ
    J Natl Cancer Inst Monogr; 2010; 2010(41):130-3. PubMed ID: 20956816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ.
    Fisher ER; Costantino J; Fisher B; Palekar AS; Paik SM; Suarez CM; Wolmark N
    Cancer; 1996 Oct; 78(7):1403-16. PubMed ID: 8839545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials.
    Petrelli F; Barni S
    Radiother Oncol; 2011 Aug; 100(2):195-9. PubMed ID: 21411161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. National Surgical Adjuvant Breast and Bowel Project.
    Fisher B; Anderson S
    World J Surg; 1994; 18(1):63-9. PubMed ID: 8197778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy.
    Kerlikowske K; Molinaro A; Cha I; Ljung BM; Ernster VL; Stewart K; Chew K; Moore DH; Waldman F
    J Natl Cancer Inst; 2003 Nov; 95(22):1692-702. PubMed ID: 14625260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of treatment for ductal carcinoma in situ of the breast in Louisiana, 1988-1999.
    Wu X; Chen VW; Ruiz B; Andrews PA; Hsieh MC; Schmidt BA; Correa CN; Fontham ET
    J La State Med Soc; 2003; 155(4):206-13. PubMed ID: 14506828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The presence of proliferative breast disease with atypia does not significantly influence outcome in early-stage invasive breast cancer treated with conservative surgery and radiation.
    Fowble B; Hanlon AL; Patchefsky A; Freedman G; Hoffman JP; Sigurdson ER; Goldstein LJ
    Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):105-15. PubMed ID: 9747827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Rudloff U; Brogi E; Brockway JP; Goldberg JI; Cranor M; Wynveen CA; Nehhozina T; Reiner AS; Patil S; Van Zee KJ
    Cancer; 2009 Mar; 115(6):1203-14. PubMed ID: 19170233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis and management of ductal carcinoma in situ (DCIS).
    Virnig BA; Shamliyan T; Tuttle TM; Kane RL; Wilt TJ
    Evid Rep Technol Assess (Full Rep); 2009 Sep; (185):1-549. PubMed ID: 20629475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
    Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.